文献速递脑血管病

围产期动脉卒中鼻内间充质干细胞治疗:2年安全性与神经发育

Perinatal Arterial Stroke Treated With Stromal Cells Intranasally: 2-Year Safety and Neurodevelopment.
PubMed 文献 · Stroke · 2025-07-14

PASSIoN研究事后分析评估10例围产期动脉缺血性卒中新生儿鼻内单剂量异体间充质干细胞(MSC)的长期安全性及神经发育结局,并与39例非MSC治疗注册队列比较。2岁时无相关不良事件,脑性瘫痪发生2例(20%),认知、行为、语言问题10%–20%,无癫痫;MSC组3月龄内囊后肢和大脑脚不对称更少,2岁时运动表现更优。

要点

  • 鼻内MSC治疗在10例新生儿中2年随访未报告相关不良事件。
  • 2岁时脑性瘫痪2例(20%),均为GMFCS I级,无运动发育迟缓。
  • 与注册队列比,MSC组3月龄内囊后肢和大脑脚不对称更少,2岁运动Z评分更优。

核心结论

  • 鼻内MSC治疗在10例围产期动脉缺血性卒中婴儿中显示长期安全性,并可能提示较文献和非MSC队列更好的运动结局。
  • 需随机对照试验确认MSC对围产期动脉缺血性卒中患儿的疗效。

研究设计与样本

  • PASSIoN研究事后分析,评估10例鼻内单剂量异体MSC治疗的围产期动脉缺血性卒中新生儿。
  • 对照为非MSC治疗注册队列39例,出生于1994–2022年且符合PASSIoN试验纳入标准。

主要发现

  • 3月龄时PASSIoN参与者平均组织丢失比率为89±21%,提示组织保留多于基于初始卒中体积的预期。
  • 2岁时无相关不良事件报告;2例(20%)发生脑性瘫痪(GMFCS I级)但无运动发育迟缓。
  • 认知、行为和语言问题影响10%至20%,无癫痫发生。
  • 与注册队列比,PASSIoN参与者3月龄MRI内囊后肢不对称更少(40% versus 81%;P=0.02)。
  • 与注册队列比,PASSIoN参与者3月龄MRI大脑脚不对称更少(10% versus 61%;P=0.01),2岁运动表现更优(中位Z评分0.3 vs -0.4;P=0.003)。

临床怎么用

  • 该结果支持鼻内MSC治疗在围产期动脉缺血性卒中新生儿中的长期安全性,但疗效尚待随机对照试验证实。

局限性

  • 本研究为事后分析,样本量小(MSC组N=10)。
  • 对照为非随机注册队列,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PASSIoN study (Perinatal Arterial Stroke Treated With Stromal Cells Intranasally) demonstrated the feasibility and short-term safety of single-dose allogeneic mesenchymal stromal cells (MSCs) administered intranasally to neonates with perinatal arterial ischemic stroke between February 2020 and April 2021. In this study, we assessed long-term safety and neurodevelopmental outcomes and explored outcome differences with a non-MSC-treated cohort. METHODS: In this post hoc analysis, we evaluated the safety of MSC administration by assessing brain tissue loss, adverse events, and neurodevelopmental outcomes of PASSIoN participants (N=10). The tissue loss ratio was calculated using semi-automatic segmentation based on neonatal and 3-month magnetic resonance imaging. At the age of 2 years, we assessed the occurrence of cerebral palsy, motor and cognitive delays (Z score <-1 SD), behavioral and language problems, visual field defects, and epilepsy. We selected a non-MSC-treated registry cohort (N=39) born between 1994 and 2022, who would have met PASSIoN trial inclusion criteria to compare magnetic resonance imaging and outcome characteristics. RESULTS: At 3 months, the mean±SD tissue loss ratio of PASSIoN participants was 89±21%, indicating more preserved tissue than expected based on initial stroke volume. By the age of 2 years, no related adverse events were reported. Two children (20%) developed cerebral palsy (Gross Motor Function Classification System I) without motor developmental delays. Cognitive, behavioral, and language problems affected 10% to 20%, and none had developed epilepsy. Compared with the registry cohort, and PASSIoN participants showed less often asymmetry of the posterior limb of the internal capsule (40% versus 81%; P=0.02) and the cerebral peduncle (10% versus 61%; P=0.01) on 3-month magnetic resonance imaging and had a better motor performance at the age of 2 years (median [interquartile range] Z score, 0.3 [0.8] versus -0.4 [1.5]; P=0.003). CONCLUSIONS: This study demonstrates the long-term safety of intranasal MSC therapy in 10 infants with perinatal arterial ischemic stroke and may suggest better motor outcomes compared with the literature and a non-MSC-treated cohort. Randomized controlled trials are required to confirm MSC efficacy for children with perinatal arterial ischemic stroke. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03356821.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Wagenaar N, Baak LM, van der Aa NE, et al. Perinatal Arterial Stroke Treated With Stromal Cells Intranasally: 2-Year Safety and Neurodevelopment. Stroke. 2025. PMID: 40654084. doi:10.1161/STROKEAHA.125.050786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。